A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors
Phase 1
110
about 3.4 years
18+
18 sites in CA, CO, FL +9
What this study is about
This trial is testing a treatment called ALTA2618 for adults with advanced solid tumors that have the AKT1 E17K mutation. The goal is to learn about how safe and effective ALTA2618 is in these patients.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take ALTA2618
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Adverse Events, Dose Limiting Toxicities
Secondary: Duration of Response (DOR), Maximum Observed Plasma Concentration (Cmax), Overall Response Rate (ORR), Overall Survival (OS), Progression-Free Survival (PFS), Terminal Half-Life (t1/2), Time to Reach Maximum Observed Plasma Concentration (Tmax)
Oncology